306 related articles for article (PubMed ID: 30013182)
1. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
Sulkowski PL; Sundaram RK; Oeck S; Corso CD; Liu Y; Noorbakhsh S; Niger M; Boeke M; Ueno D; Kalathil AN; Bao X; Li J; Shuch B; Bindra RS; Glazer PM
Nat Genet; 2018 Aug; 50(8):1086-1092. PubMed ID: 30013182
[TBL] [Abstract][Full Text] [Related]
2. Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.
Lehtonen HJ; Mäkinen MJ; Kiuru M; Laiho P; Herva R; van Minderhout I; Hogendoorn PC; Cornelisse C; Devilee P; Launonen V; Aaltonen LA
Int J Cancer; 2007 Sep; 121(6):1386-9. PubMed ID: 17520677
[TBL] [Abstract][Full Text] [Related]
3. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
4. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
5. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
Ueno D; Vasquez JC; Sule A; Liang J; van Doorn J; Sundaram R; Friedman S; Caliliw R; Ohtake S; Bao X; Li J; Ye H; Boyd K; Huang RR; Dodson J; Boutros P; Bindra RS; Shuch B
Oncotarget; 2022; 13():1054-1067. PubMed ID: 36128328
[TBL] [Abstract][Full Text] [Related]
6. Germline FH mutations presenting with pheochromocytoma.
Clark GR; Sciacovelli M; Gaude E; Walsh DM; Kirby G; Simpson MA; Trembath RC; Berg JN; Woodward ER; Kinning E; Morrison PJ; Frezza C; Maher ER
J Clin Endocrinol Metab; 2014 Oct; 99(10):E2046-50. PubMed ID: 25004247
[TBL] [Abstract][Full Text] [Related]
7. Fumarate hydratase loss promotes mitotic entry in the presence of DNA damage after ionising radiation.
Johnson TI; Costa ASH; Ferguson AN; Frezza C
Cell Death Dis; 2018 Sep; 9(9):913. PubMed ID: 30190474
[TBL] [Abstract][Full Text] [Related]
8. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Pheochromocytoma and Paraganglioma.
Fuchs TL; Luxford C; Clarkson A; Sheen A; Sioson L; Elston M; Croxson MS; Dwight T; Benn DE; Tacon L; Field M; Ahadi MS; Chou A; Clifton-Bligh RJ; Gill AJ
Am J Surg Pathol; 2023 Jan; 47(1):25-36. PubMed ID: 35993574
[TBL] [Abstract][Full Text] [Related]
9. Prospective Detection of Germline Mutation of Fumarate Hydratase in Women With Uterine Smooth Muscle Tumors Using Pathology-based Screening to Trigger Genetic Counseling for Hereditary Leiomyomatosis Renal Cell Carcinoma Syndrome: A 5-Year Single Institutional Experience.
Rabban JT; Chan E; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 May; 43(5):639-655. PubMed ID: 30741757
[TBL] [Abstract][Full Text] [Related]
10. Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma.
Zavoshi S; Lu E; Boutros PC; Zhang L; Harari A; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Wilde B; Christofk H; Shuch B
Urology; 2023 Jun; 176():106-114. PubMed ID: 36773955
[TBL] [Abstract][Full Text] [Related]
11. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
12. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
Plevová P; Hladíková A; Tesařová M
Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
[TBL] [Abstract][Full Text] [Related]
13. Uterine leiomyomas in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome can be identified through distinct clinical characteristics and typical morphology.
Uimari O; Ahtikoski A; Kämpjärvi K; Butzow R; Järvelä IY; Ryynänen M; Aaltonen LA; Vahteristo P; Kuismin O
Acta Obstet Gynecol Scand; 2021 Nov; 100(11):2066-2075. PubMed ID: 34480341
[TBL] [Abstract][Full Text] [Related]
14. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
15. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
16. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
17. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
18. Fumarate hydratase gene germline variants and mosaicism associated with pheochromocytoma and paraganglioma.
Ma X; Cui Y; Gao Y; Zhang X; Nie M; Tong A
Ann N Y Acad Sci; 2022 Oct; 1516(1):262-270. PubMed ID: 35821608
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
20. Pheochromocytoma associated with cutaneous and uterine leiomyomatosis and renal cancer in a patient with a germline mutation in the fumarate hydratase gene.
Morón M; Afonso JL; Boronat M
Endocrinol Diabetes Nutr (Engl Ed); 2020 Apr; 67(4):291-293. PubMed ID: 31133476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
